Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01609452

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)

Status
Withdrawn
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Anthera Pharmaceuticals · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when administered on top of standard-of-care to subjects with Immune Thrombocytopenic Purpura (ITP).

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlisibimod
OTHERPlacebo

Timeline

Start date
2015-12-01
Primary completion
2016-06-01
First posted
2012-06-01
Last updated
2015-07-30

Source: ClinicalTrials.gov record NCT01609452. Inclusion in this directory is not an endorsement.